Jazz Pharmaceuticals Plc 2010 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2010. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for unmet medical needs. The company markets two primary products: Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder. 2010 marked the company's first year of profitability, driven by substantial sales growth in Xyrem.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenues | $173.8 million | $128.4 million |
| Net Product Sales | $170.0 million | $115.1 million |
| Net Income | $32.8 million | ($6.8 million) loss |
| Operating Income | $57.8 million | $15.9 million |
| Research & Development | $25.6 million | $36.6 million |
| Cash and Cash Equivalents (Year End) | $44.8 million | $15.6 million |
| Long-Term Debt (Principal) | $41.7 million | $119.5 million |
| Working Capital | $14.5 million | ($22.3 million) deficit |
Margins: Gross margin on product sales was approximately 92% in 2010 (Cost of product sales was $13.6 million on $170.0 million sales). Operating margin improved significantly to 33% in 2010 compared to 12% in 2009.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 35% year-over-year. Net product sales grew 48%, driven by a 47% increase in Xyrem sales (to $142.6 million) and a 49% increase in Luvox CR sales (to $27.4 million). Growth was attributed to price increases and volume growth.
- Profitability: The company transitioned from a net loss of $6.8 million in 2009 to a net income of $32.8 million in 2010.
- Debt Restructuring: In June 2010, the company repaid all outstanding senior secured notes (totaling $119.5 million) using cash on hand, proceeds from a $56.8 million equity offering, and a new $50.0 million term loan. This reduced the interest rate from 15% to a variable rate of 5.75% and significantly lowered interest expense.
- Operating Expenses: R&D expenses decreased 30% due to lower spending on the JZP-6 fibromyalgia program following an FDA Complete Response Letter. SG&A expenses increased 18% due to headcount growth and legal expenses.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Pipeline:
- JZP-6 (Fibromyalgia): The FDA issued a Complete Response Letter (CRL) in October 2010, stating the New Drug Application (NDA) could not be approved in its present form. The company has not finalized plans for continued development.
- JZP-8 (Epilepsy): Development continues with plans for an additional Phase II study in late 2011.
- Luvox CR: The company is in discussions with the FDA to remove the social anxiety disorder indication from the label, which may impact future sales.
Key Risks and Contingencies:
- Generic Competition: Roxane Laboratories filed an Abbreviated New Drug Application (ANDA) for a generic version of Xyrem in October 2010. Jazz filed a lawsuit in response. Generic approval could materially adversely affect sales. Similarly, litigation regarding generic Luvox CR is ongoing (Actavis) or settled (Anchen, with generic launch expected Feb 2013).
- Supply Chain: The company relies on single-source suppliers for active pharmaceutical ingredients (API) and manufacturing. Obtaining DEA quotas for sodium oxybate is a critical risk factor.
- Regulatory: Xyrem is subject to a Risk Evaluation and Mitigation Strategy (REMS) and a black box warning. The company is subject to a Corporate Integrity Agreement through mid-2012.
Unusual Items:
- Loss on Extinguishment of Debt: A one-time charge of $12.3 million was recorded in 2010 related to the prepayment of senior secured notes.
- Revenue Recognition Change: In Q4 2010, the company changed its revenue recognition policy for Luvox CR from dispensed-based to shipment-based, recognizing $2.0 million of previously deferred revenue.
Investor Verification Checklist
- Generic Litigation Status: Verify the current status of the lawsuit against Roxane Laboratories regarding Xyrem and the pending litigation against Actavis regarding Luvox CR.
- JZP-6 Development Plan: Confirm if the company has decided to pursue additional clinical studies for JZP-6 following the FDA CRL and the associated costs.
- DEA Quota Sufficiency: Assess whether current and projected DEA quotas for sodium oxybate are sufficient to meet demand for Xyrem and JZP-6.
- Luvox CR Labeling: Monitor the outcome of discussions with the FDA regarding the removal of the social anxiety disorder indication.
- Debt Covenants: Review compliance with the new credit agreement covenants, specifically the minimum liquidity requirements ($10M until March 2011, $20M thereafter).